Literature DB >> 9010648

Drug treatment of HIV-related opportunistic infections.

M E Klepser1, T B Klepser.   

Abstract

The AIDS epidemic has led to the emergence of several disease entities which in the pre-AIDS era were rare or seemingly innocuous. Experience of treating these diseases varies. In some instances, such as Pneumocystis carinii pneumonia, there is an abundance of published literature to direct our course of action. However, for many of these newly recognised diseases our treatment experience is limited. Furthermore, in many instances, well controlled trials evaluating treatment modalities in the AIDS population are lacking. We have identified 13 disease entities (P. carinii pneumonia, toxoplasmosis, cryptococcosis, histoplasmosis, Mycobacterium tuberculosis, Mycobacterium avium complex, cytomegalovirus, coccidioidomycosis, isosporiasis, candidosis, Kaposi's sarcoma, herpes simplex virus, and varicella zoster virus) and have reviewed the current literature with regard to their treatment.

Entities:  

Mesh:

Year:  1997        PMID: 9010648     DOI: 10.2165/00003495-199753010-00004

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  173 in total

Review 1.  Disseminated histoplasmosis in the acquired immune deficiency syndrome: clinical findings, diagnosis and treatment, and review of the literature.

Authors:  L J Wheat; P A Connolly-Stringfield; R L Baker; M F Curfman; M E Eads; K S Israel; S A Norris; D H Webb; M L Zeckel
Journal:  Medicine (Baltimore)       Date:  1990-11       Impact factor: 1.889

2.  Long-term follow-up of patients with AIDS on maintenance therapy for toxoplasmosis.

Authors:  C Leport; C Tournerie; G Raguin; J Fernandez-Martin; T Niyongabo; J L Vildé
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-03       Impact factor: 3.267

3.  Disseminated ecthymatous herpes varicella-zoster virus infection in patients with acquired immunodeficiency syndrome.

Authors:  I H Gilson; J H Barnett; M A Conant; O L Laskin; J Williams; P G Jones
Journal:  J Am Acad Dermatol       Date:  1989-04       Impact factor: 11.527

4.  Trimethoprim-sulfamethoxazole versus pentamidine for Pneumocystis carinii pneumonia in AIDS patients: results of a large prospective randomized treatment trial.

Authors:  N C Klein; F P Duncanson; T H Lenox; C Forszpaniak; C B Sherer; H Quentzel; M Nunez; M Suarez; O Kawwaff; A Pitta-Alvarez
Journal:  AIDS       Date:  1992-03       Impact factor: 4.177

5.  Treatment of systemic mycoses with ketoconazole: emphasis on toxicity and clinical response in 52 patients. National Institute of Allergy and Infectious Diseases collaborative antifungal study.

Authors:  W E Dismukes; A M Stamm; J R Graybill; P C Craven; D A Stevens; R L Stiller; G A Sarosi; G Medoff; C R Gregg; H A Gallis; B T Fields; R L Marier; T A Kerkering; L G Kaplowitz; G Cloud; C Bowles; S Shadomy
Journal:  Ann Intern Med       Date:  1983-01       Impact factor: 25.391

6.  Clindamycin/primaquine versus trimethoprim-sulfamethoxazole as primary therapy for Pneumocystis carinii pneumonia in AIDS: a randomized, double-blind pilot trial.

Authors:  E Toma; S Fournier; M Dumont; P Bolduc; H Deschamps
Journal:  Clin Infect Dis       Date:  1993-08       Impact factor: 9.079

7.  Survival of patients with acquired immune deficiency syndrome and disseminated Mycobacterium avium complex infection with and without antimycobacterial chemotherapy.

Authors:  C R Horsburgh; J A Havlik; D A Ellis; E Kennedy; S A Fann; R E Dubois; S E Thompson
Journal:  Am Rev Respir Dis       Date:  1991-09

8.  Ketoconazole for treatment of disseminated coccidioidomycosis.

Authors:  A Catanzaro; H Einstein; B Levine; J B Ross; R Schillaci; J Fierer; P J Friedman
Journal:  Ann Intern Med       Date:  1982-04       Impact factor: 25.391

9.  A placebo-controlled trial of maintenance therapy with fluconazole after treatment of cryptococcal meningitis in the acquired immunodeficiency syndrome. California Collaborative Treatment Group.

Authors:  S A Bozzette; R A Larsen; J Chiu; M A Leal; J Jacobsen; P Rothman; P Robinson; G Gilbert; J A McCutchan; J Tilles
Journal:  N Engl J Med       Date:  1991-02-28       Impact factor: 91.245

10.  Weekly oral etoposide in patients with Kaposi's sarcoma associated with human immunodeficiency virus infection: a phase I multicenter trial of the AIDS Clinical Trials Group.

Authors:  J Paredes; J O Kahn; W P Tong; M L Feldstein; S Lin; J M Bennett; C E Metroka; L Ratner; S E Krown
Journal:  J Acquir Immune Defic Syndr Hum Retrovirol       Date:  1995-06-01
View more
  18 in total

1.  CoMFA analysis of tgDHFR and rlDHFR based on antifolates with 6-5 fused ring system using the all-orientation search (AOS) routine and a modified cross-validated r(2)-guided region selection (q(2)-GRS) routine and its initial application.

Authors:  Aleem Gangjee; Xin Lin; Lisa R Biondo; Sherry F Queener
Journal:  Bioorg Med Chem       Date:  2010-01-06       Impact factor: 3.641

2.  Potent dual thymidylate synthase and dihydrofolate reductase inhibitors: classical and nonclassical 2-amino-4-oxo-5-arylthio-substituted-6-methylthieno[2,3-d]pyrimidine antifolates.

Authors:  Aleem Gangjee; Yibin Qiu; Wei Li; Roy L Kisliuk
Journal:  J Med Chem       Date:  2008-09-25       Impact factor: 7.446

3.  Design, synthesis, and molecular modeling of novel pyrido[2,3-d]pyrimidine analogues as antifolates; application of Buchwald-Hartwig aminations of heterocycles.

Authors:  Aleem Gangjee; Ojas A Namjoshi; Sudhir Raghavan; Sherry F Queener; Roy L Kisliuk; Vivian Cody
Journal:  J Med Chem       Date:  2013-05-21       Impact factor: 7.446

4.  Novel non-classical C9-methyl-5-substituted-2,4-diaminopyrrolo[2,3-d]pyrimidines as potential inhibitors of dihydrofolate reductase and as anti-opportunistic agents.

Authors:  Aleem Gangjee; Jie Yang; Sherry F Queener
Journal:  Bioorg Med Chem       Date:  2006-09-28       Impact factor: 3.641

5.  Isolation of rat dihydrofolate reductase gene and characterization of recombinant enzyme.

Authors:  Y Wang; J A Bruenn; S F Queener; V Cody
Journal:  Antimicrob Agents Chemother       Date:  2001-09       Impact factor: 5.191

6.  Synthesis, biological evaluation and molecular modeling studies of N6-benzyladenosine analogues as potential anti-toxoplasma agents.

Authors:  Young Ah Kim; Ashoke Sharon; Chung K Chu; Reem H Rais; Omar N Al Safarjalani; Fardos N M Naguib; Mahmoud H el Kouni
Journal:  Biochem Pharmacol       Date:  2007-01-21       Impact factor: 5.858

7.  2,4-Diamino-5-methyl-6-substituted arylthio-furo[2,3-d]pyrimidines as novel classical and nonclassical antifolates as potential dual thymidylate synthase and dihydrofolate reductase inhibitors.

Authors:  Aleem Gangjee; Hiteshkumar D Jain; Jaclyn Phan; Xin Guo; Sherry F Queener; Roy L Kisliuk
Journal:  Bioorg Med Chem       Date:  2009-12-26       Impact factor: 3.641

8.  Design, synthesis, and X-ray crystal structure of classical and nonclassical 2-amino-4-oxo-5-substituted-6-ethylthieno[2,3-d]pyrimidines as dual thymidylate synthase and dihydrofolate reductase inhibitors and as potential antitumor agents.

Authors:  Aleem Gangjee; Wei Li; Roy L Kisliuk; Vivian Cody; Jim Pace; Jennifer Piraino; Jennifer Makin
Journal:  J Med Chem       Date:  2009-08-13       Impact factor: 7.446

9.  The effect of 5-alkyl modification on the biological activity of pyrrolo[2,3-d]pyrimidine containing classical and nonclassical antifolates as inhibitors of dihydrofolate reductase and as antitumor and/or antiopportunistic infection agents.

Authors:  Aleem Gangjee; Hiteshkumar D Jain; Sherry F Queener; Roy L Kisliuk
Journal:  J Med Chem       Date:  2008-07-08       Impact factor: 7.446

10.  Design and synthesis of classical and nonclassical 6-arylthio-2,4-diamino-5-ethylpyrrolo[2,3-d]pyrimidines as antifolates.

Authors:  Aleem Gangjee; Yibin Zeng; Tina Talreja; John J McGuire; Roy L Kisliuk; Sherry F Queener
Journal:  J Med Chem       Date:  2007-06-07       Impact factor: 7.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.